Histology of Visceral and Subcutaneous Fat

Both are “fat” — so what is different?

2026-10-13

Goals of this lecture

  • Describe the histology of white adipose tissue
  • Explain the histological differences between visceral and subcutaneous fat
  • Explain their metabolic and endocrine differences (lipolysis, portal vein, adipokines)
  • Use the adipose tissue expandability hypothesis to explain why “where fat is stored” matters

Sources are given at the bottom of each slide. For details, see the Book version and the reference list on the final slide.

Classification of adipose tissue

  • White: storage and endocrine function. Unilocular (one large lipid droplet)
  • Brown: heat production via UCP1. Present even in adults, in the neck, supraclavicular region, etc.
  • Beige: appears within white fat; strongly expresses UCP1 upon stimulation

Both visceral and subcutaneous fat are white fat. The difference is “location (depot)” and “character”

Sources: Pawlina and Ross (2020); Cinti (2005); Cypess et al. (2009); Wu et al. (2012); Tchkonia et al. (2013)

Location and venous drainage

Visceral fat (VAT) Subcutaneous fat (SAT)
Main sites Mesentery, greater omentum Abdominal subcutaneous (superficial/deep), gluteal and femoral
Veins Portal vein → liver Systemic circulation
  • The deep layer of abdominal subcutaneous fat correlates strongly with insulin sensitivity (the superficial layer weakly)
  • Japanese criteria: visceral fat area 100 cm²; corresponding waist circumference men 85 / women 90 cm

Sources: Ibrahim (2010); Kelley et al. (2000); Examination Committee of Criteria for ’Obesity Disease’ in Japan and Japan Society for the Study of Obesity (2002)

Histology of white adipose tissue

  • In HE sections, lipids are dissolved out so cells appear as vacuoles, with the nucleus pushed to the edge
  • To see fat: frozen sections + Oil Red O
  • Adipocyte contents are more than 95% triglyceride
  • Adult adipocyte number is nearly constant; about 10% are renewed each year

Sources: Pawlina and Ross (2020); Mehlem et al. (2013); Arner (2005); Spalding et al. (2008)

Adipose tissue is an “organ”

Adipocytes + stromal vascular fraction (SVF) + extracellular matrix + vessels and nerves

  • Preadipocytes (the source of hyperplasia)
  • Vascular endothelium, etc. (adipose tissue is rich in vessels and nerves)
  • Immune cells (macrophages increase in obesity and correlate with cell size)

Sources: Rosen and Spiegelman (2014); Cinti (2005); Weisberg et al. (2003)

What happens in obesity

  • Hypertrophy → oxygen diffusion limit → hypoxia
  • In obesity, more than 90% of macrophages cluster around dead adipocytes (crown-like structures). Cell death correlates with cell size
  • TNF-α is involved in insulin resistance (rodents)
  • Adipocyte size predicts type 2 diabetes independently of percent body fat

Sources: Sun et al. (2011); Cinti et al. (2005); Hotamisligil et al. (1993); Weyer et al. (2000)

Histological differences

Item Visceral fat Subcutaneous fat
Cellularity, vessels, nerves More Fewer
Macrophages About 2× subcutaneous in omentum Fewer
Progenitor lipid accumulation & proliferation Low in omentum High
GR, AR More Fewer

Sources: Ibrahim (2010); Cancello et al. (2006); Tchkonia et al. (2005)

Adipocyte size: reports differ

  • Comparison in women: subcutaneous adipocytes are about 50% larger than omental ones
  • Review: visceral fat has a higher proportion of large adipocytes

→ One cannot say “larger/smaller because it is visceral.” Regardless of site, hypertrophy is a risk

Sources: Van Harmelen et al. (1998); Ibrahim (2010); Weyer et al. (2000)

Developmental origin and local hormonal environment

  • Depot properties persist in culture; expression of developmental genes differs by depot
  • In mice, Wt1-expressing cells contribute to all six visceral depots but not to subcutaneous fat
  • Omental stromal cells can make cortisol via 11β-HSD1 (almost none in subcutaneous) → “Cushing’s disease of the omentum”

Sources: Tchkonia et al. (2005); Gesta et al. (2006); Chau et al. (2014); Bujalska et al. (1997)

Lipolysis

Visceral fat is a high-turnover fat that “releases easily”

  • Visceral adipocytes are prone to lipolysis and more insulin-resistant
  • Under hormonal stimulation, visceral fat releases more fatty acids (the difference widens in obesity)
  • In humans, four adrenergic receptor subtypes are involved (β3 predominates in rodents)
  • With moderate weight loss, visceral fat is lost preferentially

Sources: Ibrahim (2010); Arner (2005); Chaston and Dixon (2008)

The portal hypothesis

Free fatty acids from visceral fat → portal vein → liver

  • Of the FFA reaching the liver, the visceral-derived share is under 10% to about 50%
  • The more visceral fat, the higher the share (steeper slope in women)
  • Contributes to dyslipidaemia, hyperinsulinaemia and impaired glucose tolerance

Sources: Björntorp (1990); Nielsen et al. (2004); Arner (2005)

Adipokines

Relationship to visceral / subcutaneous fat
Adiponectin Low in obesity. Negatively correlated with visceral fat area
Leptin Secretion from subcutaneous fat is 2–3× that from omentum
IL-6 Release from omentum is 2–3× that from subcutaneous fat
PAI-1 Plasma level correlates with visceral fat area (not with subcutaneous)

Sources: Arita et al. (1999); Ryo et al. (2004); Van Harmelen et al. (1998); Fried et al. (1998); Shimomura et al. (1996)

Gluteofemoral fat is protective

  • A larger gluteofemoral fat mass is independently associated with favourable lipid and glucose metabolism
  • It stores fatty acids long-term, protecting against the harm of ectopic fat
  • Upper-body fat (visceral + abdominal subcutaneous) is an independent risk

Sources: Manolopoulos et al. (2010); Lee et al. (2013)

Sex, age and ethnicity

  • Visceral fat increased significantly only in women who transitioned to menopause (fall in estradiol)
  • With ageing: lower-body subcutaneous fat↓, visceral fat↑, ectopic fat↑ (independently of body weight)
  • With ageing, progenitors shift to a pro-inflammatory, senescence-like state
  • In Asians, risk rises from a lower BMI. In Japan, BMI ≥ 25 is obesity. At BMI ≥ 25, BMI and visceral fat are barely correlated

Sources: Lovejoy et al. (2008); Kuk et al. (2009); Tchkonia et al. (2010); WHO Expert Consultation (2004); Examination Committee of Criteria for ’Obesity Disease’ in Japan and Japan Society for the Study of Obesity (2002); 菅波孝祥 (2024)

The adipose tissue expandability hypothesis

The key is not obesity itself but “the limit of adipose tissue’s expansion capacity”

  • The limit is determined by genes and environment
  • Beyond the limit, lipid accumulates in other tissues
  • Ectopic lipid causes insulin resistance, cell death and inflammation (lipotoxicity)

Sources: Virtue and Vidal-Puig (2010)

Childhood obesity and adipocyte number

  • In obese children, cell number and size increase early from just after age 1, and by age 11 exceed the mean cell number of non-obese adults
  • Adult cell number is constant and does not decrease with weight loss (number is set in childhood to adolescence)
  • In adults, the more hyperplastic (“many small cells”), the better the insulin sensitivity. The hypertrophic type produces 70% fewer new cells (independent of sex and body weight)

However, no study was found that directly shows “overweight in childhood → greater expansion capacity”

Sources: Knittle et al. (1979); Spalding et al. (2008); Arner et al. (2010); Eriksson-Hogling et al. (2015)

Two examples supporting the hypothesis

  • Lipodystrophy: leptin deficiency, insulin resistance, hypertriglyceridaemia, fatty liver. 4 months of leptin replacement: HbA1c −1.9%, triglycerides −60%, liver volume −28%
  • Pioglitazone (PPARγ activation): over 16 weeks, body weight and fat mass increased, but subcutaneous fat↑ and visceral fat↓, with improved insulin sensitivity
  • But beware fluid retention / worsening heart failure and increased fracture risk

Sources: Garg (2004); Oral et al. (2002); Lehmann et al. (1995); Miyazaki et al. (2002); Nesto et al. (2003); Loke et al. (2009)

Hands-on

Run the models in the browser in Chapter 7 of the Book version

  1. Hypertrophy or hyperplasia: compute mean diameter from body fat mass and cell number
  2. When adipose tissue overflows: changing capacity changes visceral and ectopic fat even with the same weight gain

The model’s allocation (85/15/70/30%) is the author’s assumption, not a literature value. 7,700 kcal/kg is a rule of thumb (Hall 2008)

Summary

  • Visceral fat: rich in cells, vessels, nerves and immune cells; active lipolysis; drains via the portal vein to the liver
  • Subcutaneous fat: progenitors with high lipid accumulation and proliferative capacity; acts as a reservoir (gluteofemoral fat is protective)
  • Metabolism is determined not only by the amount of fat but by its distribution and expansion capacity

Sources: Ibrahim (2010); Tchkonia et al. (2005); Manolopoulos et al. (2010); Virtue and Vidal-Puig (2010)

References

Arita, Y., S. Kihara, N. Ouchi, et al. 1999. “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.” Biochemical and Biophysical Research Communications 257 (1): 79–83. https://doi.org/10.1006/bbrc.1999.0255.
Arner, E., P. O. Westermark, K. L. Spalding, et al. 2010. “Adipocyte turnover: relevance to human adipose tissue morphology.” Diabetes 59 (1): 105–9. https://doi.org/10.2337/db09-0942.
Arner, P. 2005. “Human fat cell lipolysis: biochemistry, regulation and clinical role.” Best Practice & Research. Clinical Endocrinology & Metabolism 19 (4): 471–82. https://doi.org/10.1016/j.beem.2005.07.004.
Björntorp, P. 1990. “"Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.” Arteriosclerosis (Dallas, Tex.) 10 (4): 493–96.
Bujalska, I. J., S. Kumar, and P. M. Stewart. 1997. “Does central obesity reflect "Cushing’s disease of the omentum"?” Lancet (London, England) 349 (9060): 1210–13. https://doi.org/10.1016/S0140-6736(96)11222-8.
Cancello, R., J. Tordjman, C. Poitou, et al. 2006. “Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity.” Diabetes 55 (6): 1554–61. https://doi.org/10.2337/db06-0133.
Chaston, T. B., and J. B. Dixon. 2008. “Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review.” International Journal of Obesity (2005) 32 (4): 619–28. https://doi.org/10.1038/sj.ijo.0803761.
Chau, Y. Y., R. Bandiera, A. Serrels, et al. 2014. “Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source.” Nature Cell Biology 16 (4): 367–75. https://doi.org/10.1038/ncb2922.
Cinti, S. 2005. “The adipose organ.” Prostaglandins, Leukotrienes, and Essential Fatty Acids 73 (1): 9–15. https://doi.org/10.1016/j.plefa.2005.04.010.
Cinti, S., G. Mitchell, G. Barbatelli, et al. 2005. “Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.” Journal of Lipid Research 46 (11): 2347–55. https://doi.org/10.1194/jlr.M500294-JLR200.
Cypess, A. M., S. Lehman, G. Williams, et al. 2009. “Identification and importance of brown adipose tissue in adult humans.” The New England Journal of Medicine 360 (15): 1509–17. https://doi.org/10.1056/NEJMoa0810780.
Eriksson-Hogling, D., D. P. Andersson, J. Bäckdahl, et al. 2015. “Adipose tissue morphology predicts improved insulin sensitivity following moderate or pronounced weight loss.” International Journal of Obesity (2005) 39 (6): 893–98. https://doi.org/10.1038/ijo.2015.18.
Examination Committee of Criteria for ’Obesity Disease’ in Japan, and Japan Society for the Study of Obesity. 2002. “New criteria for ’obesity disease’ in Japan.” Circulation Journal : Official Journal of the Japanese Circulation Society 66 (11): 987–92. https://doi.org/10.1253/circj.66.987.
Fried, S. K., D. A. Bunkin, and A. S. Greenberg. 1998. “Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.” The Journal of Clinical Endocrinology and Metabolism 83 (3): 847–50. https://doi.org/10.1210/jcem.83.3.4660.
Garg, A. 2004. “Acquired and inherited lipodystrophies.” The New England Journal of Medicine 350 (12): 1220–34. https://doi.org/10.1056/NEJMra025261.
Gesta, S., M. Blüher, Y. Yamamoto, et al. 2006. “Evidence for a role of developmental genes in the origin of obesity and body fat distribution.” Proceedings of the National Academy of Sciences of the United States of America 103 (17): 6676–81. https://doi.org/10.1073/pnas.0601752103.
Hall, K. D. 2008. “What is the required energy deficit per unit weight loss?” International Journal of Obesity (2005) 32 (3): 573–76. https://doi.org/10.1038/sj.ijo.0803720.
Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. “Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.” Science (New York, N.Y.) 259 (5091): 87–91. https://doi.org/10.1126/science.7678183.
Ibrahim, M. M. 2010. “Subcutaneous and visceral adipose tissue: structural and functional differences.” Obesity Reviews : An Official Journal of the International Association for the Study of Obesity 11 (1): 11–18. https://doi.org/10.1111/j.1467-789X.2009.00623.x.
Kelley, D. E., F. L. Thaete, F. Troost, T. Huwe, and B. H. Goodpaster. 2000. “Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance.” American Journal of Physiology. Endocrinology and Metabolism 278 (5): E941–8. https://doi.org/10.1152/ajpendo.2000.278.5.E941.
Knittle, J. L., K. Timmers, F. Ginsberg-Fellner, R. E. Brown, and D. P. Katz. 1979. “The growth of adipose tissue in children and adolescents. Cross-sectional and longitudinal studies of adipose cell number and size.” The Journal of Clinical Investigation 63 (2): 239–46. https://doi.org/10.1172/JCI109295.
Kuk, J. L., T. J. Saunders, L. E. Davidson, and R. Ross. 2009. “Age-related changes in total and regional fat distribution.” Ageing Research Reviews 8 (4): 339–48. https://doi.org/10.1016/j.arr.2009.06.001.
Lee, M. J., Y. Wu, and S. K. Fried. 2013. “Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications.” Molecular Aspects of Medicine 34 (1): 1–11. https://doi.org/10.1016/j.mam.2012.10.001.
Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).” The Journal of Biological Chemistry 270 (22): 12953–56. https://doi.org/10.1074/jbc.270.22.12953.
Loke, Y. K., S. Singh, and C. D. Furberg. 2009. “Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.” CMAJ : Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne 180 (1): 32–39. https://doi.org/10.1503/cmaj.080486.
Lovejoy, J. C., C. M. Champagne, L. de Jonge, H. Xie, and S. R. Smith. 2008. “Increased visceral fat and decreased energy expenditure during the menopausal transition.” International Journal of Obesity (2005) 32 (6): 949–58. https://doi.org/10.1038/ijo.2008.25.
Manolopoulos, K. N., F. Karpe, and K. N. Frayn. 2010. “Gluteofemoral body fat as a determinant of metabolic health.” International Journal of Obesity (2005) 34 (6): 949–59. https://doi.org/10.1038/ijo.2009.286.
Mehlem, A., C. E. Hagberg, L. Muhl, U. Eriksson, and A. Falkevall. 2013. “Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease.” Nature Protocols 8 (6): 1149–54. https://doi.org/10.1038/nprot.2013.055.
Miyazaki, Y., A. Mahankali, M. Matsuda, et al. 2002. “Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.” The Journal of Clinical Endocrinology and Metabolism 87 (6): 2784–91. https://doi.org/10.1210/jcem.87.6.8567.
Nesto, R. W., D. Bell, R. O. Bonow, et al. 2003. “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.” Circulation 108 (23): 2941–48. https://doi.org/10.1161/01.CIR.0000103683.99399.7E.
Nielsen, S., Z. Guo, C. M. Johnson, D. D. Hensrud, and M. D. Jensen. 2004. “Splanchnic lipolysis in human obesity.” The Journal of Clinical Investigation 113 (11): 1582–88. https://doi.org/10.1172/JCI21047.
Oral, E. A., V. Simha, E. Ruiz, et al. 2002. “Leptin-replacement therapy for lipodystrophy.” The New England Journal of Medicine 346 (8): 570–78. https://doi.org/10.1056/NEJMoa012437.
Pawlina, W., and M. H. Ross. 2020. Histology: A Text and Atlas: With Correlated Cell and Molecular Biology. 8th ed. Wolters Kluwer.
Rosen, E. D., and B. M. Spiegelman. 2014. “What we talk about when we talk about fat.” Cell 156 (1-2): 20–44. https://doi.org/10.1016/j.cell.2013.12.012.
Ryo, M., T. Nakamura, S. Kihara, et al. 2004. “Adiponectin as a biomarker of the metabolic syndrome.” Circulation Journal : Official Journal of the Japanese Circulation Society 68 (11): 975–81. https://doi.org/10.1253/circj.68.975.
Shimomura, I., T. Funahashi, M. Takahashi, et al. 1996. “Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.” Nature Medicine 2 (7): 800–803. https://doi.org/10.1038/nm0796-800.
Spalding, K. L., E. Arner, P. O. Westermark, et al. 2008. “Dynamics of fat cell turnover in humans.” Nature 453 (7196): 783–87. https://doi.org/10.1038/nature06902.
Sun, K., C. M. Kusminski, and P. E. Scherer. 2011. “Adipose tissue remodeling and obesity.” The Journal of Clinical Investigation 121 (6): 2094–101. https://doi.org/10.1172/JCI45887.
Tchkonia, T., D. E. Morbeck, T. Von Zglinicki, et al. 2010. “Fat tissue, aging, and cellular senescence.” Aging Cell 9 (5): 667–84. https://doi.org/10.1111/j.1474-9726.2010.00608.x.
Tchkonia, T., Y. D. Tchoukalova, N. Giorgadze, et al. 2005. “Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots.” American Journal of Physiology. Endocrinology and Metabolism 288 (1): E267–77. https://doi.org/10.1152/ajpendo.00265.2004.
Tchkonia, T., T. Thomou, Y. Zhu, et al. 2013. “Mechanisms and metabolic implications of regional differences among fat depots.” Cell Metabolism 17 (5): 644–56. https://doi.org/10.1016/j.cmet.2013.03.008.
Van Harmelen, V., S. Reynisdottir, P. Eriksson, et al. 1998. “Leptin secretion from subcutaneous and visceral adipose tissue in women.” Diabetes 47 (6): 913–17. https://doi.org/10.2337/diabetes.47.6.913.
Virtue, S., and A. Vidal-Puig. 2010. “Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome–an allostatic perspective.” Biochimica Et Biophysica Acta 1801 (3): 338–49. https://doi.org/10.1016/j.bbalip.2009.12.006.
Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and Ferrante AW Jr. 2003. “Obesity is associated with macrophage accumulation in adipose tissue.” The Journal of Clinical Investigation 112 (12): 1796–808. https://doi.org/10.1172/JCI19246.
Weyer, C., J. E. Foley, C. Bogardus, P. A. Tataranni, and R. E. Pratley. 2000. “Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance.” Diabetologia 43 (12): 1498–506. https://doi.org/10.1007/s001250051560.
WHO Expert Consultation. 2004. “Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.” Lancet (London, England) 363 (9403): 157–63. https://doi.org/10.1016/S0140-6736(03)15268-3.
Wu, J., P. Boström, L. M. Sparks, et al. 2012. “Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.” Cell 150 (2): 366–76. https://doi.org/10.1016/j.cell.2012.05.016.
菅波孝祥. 2024. “加齢による皮下脂肪萎縮の分子基盤の解明.” コスメトロジー研究報告(コーセーコスメトロジー研究財団) 32: 109–13. https://www.kose-cosmetology.or.jp/research_report/archives/2024/fullVersion/Cosmetology_Vol32_2024_p109-113_Takayoshi_Suganuma.pdf.